START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
Completed
Amgen
Phase 4
2004-07-01
The purpose of this research is to study the effects and safety of Sensipar approved by the
Food and Drug Administration (FDA) in patients with kidney failure who are being treated with
dialysis and have uncontrolled secondary hyperparathyroidism (HPT).
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism
Completed
Amgen
Phase 4
2005-08-01
The purpose of this study is to compare the proportion of chronic kidney disease (CKD)
subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of
vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease
Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment
targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P)
product.
A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)
Completed
Amgen
2004-12-01
Objectives include description of current practices; assessment over time of K/DOQI goals,
clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and
the impact of Sensipar® on these parameters
Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets
Completed
Children's Mercy Hospital Kansas City
Phase 1
2005-06-01
This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH)
secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators
are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by
achieving better control of PTH secretion.
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events
Completed
Amgen
Phase 3
2006-08-22
The purpose of this study is to evaluate the effects of cinacalcet (cinacalcet HCl or
Sensipar®/Mimpara®) on cardiovascular events and death in chronic kidney disease (CKD)
patients with secondary hyperparathyroidism (HPT) who are receiving dialysis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
